One of my core beliefs after running the Jubak Picks portfolio for more than 20 years now is that when the reason I picked a stock to buy evaporates, then it’s time to sell. So today (June 21) I’m selling Starbucks (SBUX) out of my Jubak Picks portfolio....
Selling MGM Resorts on escalating China trade war fears
I still believe in all the catalysts that I touted for MGM Resorts International (MGM) for late this year–yes, the company’s new Macao casino will give the company more exposure to that market, yes, a wave of states legalizing sports gambling plays to...
New catalysts lining up for MGM Resorts–I’ll hold in my Jubak Picks Portfolio for the moment of recognition
Shares of MGM Resorts International (MGM) peaked for 2018 (so far) at $38.03 on January 29, 2018 and since then the trend has been brutally downward. The stock’s 50-day moving average broke below its 200-day moving average (a moment that technical analysts...
Adding Microsoft to my Jubak Picks portfolio–hoping for a July “miss” like that in April
As I wrote in Part 3 of my Special Report “Investing in a Late Cycle Market,” (available to subscribers to my paid JubakAM.com site), I’m adding Microsoft to my Jubak Picks portfolio. The April third quarter earnings “miss” sets Microsoft...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
AT&T acquisition of Time Warner clears courts–let the media frenzy begin (and here’s what I’d buy)
Yesterday after the close of trading Judge Richard Leon gave the go-ahead to AT&T’s (T) acquisition of Time Warner, the owner of HBO and other content. The ruling is a green light to other vertical mergers in the media sector. The judge rejected the...
Time to further lighten up on emerging markets: Selling Arcos Dorados out of Jubak Picks
Back when emerging markets started to break down, I sold my positions in Argentina. Then it looked like the damage might be limited to that country. Not though it’s clear that the whole sector is under pressure and that investors trying to avoid the next...
Book keeping changes: Statoil (STO) changes its name and ticker to Equinor (EQNR)
A change in the name and ticker of portfolio holding Statoil (STO). The explanation offered by the company is that it wanted to remove “oil” from its name to better reflect the company’s increasing emphasis on other forms of energy including wind...
Adding shares of Valero Energy to my Jubak Picks Portfolio
Last night on my JubakAM.com and JugglingWithKnives.com subscription sites I laid out the case argued by Morgan Stanley for believing that distillate prices are heading higher in the face of a tight supplies for these refinery products. One of the refiners Morgan...
Stock or options, Nektar needs some understanding and patience now
It hasn’t exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock, which I hold in my Jubak Picks portfolio, is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike...
Nvidia crushes earnings; stock falls after hours
Okay, if you’re a trader I sort of understand selling Nvidia (NVDA) after today’s earnings report: Sell on the news; How can it get better? How long can the company keep it up? After all, the stock closed today just pennies below it’s all time high....
No surprise: Oil moves higher on day after U.S. pulls out of Iran nuclear deal
Some days you need to search for an explanation for a market move. Other days the explanation hits you over the head. Today crude oil is up, in a strong but orderly move. Two catalysts. First, yesterday President Donald Trump announced that the U.S. would pull out of...
SolarEdge Technologies beats on earnings and revenue; raises guidance
SolarEdge Technologies (SEDG), a member of my Jubak Picks portfolio, reported first quarter earnings today after the New York markets closed of 87 cents a share, 7 cents a share better than Wall Street projections. Revenue climbed 82.4% year over year (and 10.8% from...
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can’t find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my...
Israel’s Prime Minister announces major statement Monday night on Iranian nuclear program
Israeli Prime Minister Benjamin Netanyahu has announced that he will make a statement at 8 p.m. Tel Aviv time tonight on a “significant development” regarding the Iranian nuclear pact. (As best as I can do the conversions, 8 p.m. in Tel Aviv is 1 p.m. in New York.)...
Statoil drops after 33% jump in profit falls short of Wall Street hopes
There’s no pleasing the market these days. Shares of Statoil (STO) fell 1.54% to $24.96 today after the company reported first quarter earnings of $4.4 billion, its highest quarterly profit in three years and 33% higher than in the first quarter of 2017. But the...
Oil continues to move higher on Middle East fears
Oil futures in New York settled at their highest since December 2014. U.S. benchmark West Texas Intermediate climbed 0.35% to close at $68.88 a barrel. International benchmark Brent crude rose 0.88% to $74.71 a barrel. The gains were unusual in that the U.S. dollar...
Raising target price on Danaher after earnings beat today
Danaher (DHR) reported fourth quarter earnings of 80 cents a share before the market opened today, April 19. That was 3 cents a share ahead of Wall Street projections. Revenue climbed 10.9% year over year to $5.09 billion. The Wall Street consensus called for $4.97...
Oil prices up again on inventories, Middle East fears, OPEC price goals
West Texas Intermediate crude climbed 3.16% today to $68.80 a barrel. Futures for May delivery moved over $68 a barrel for the first time in three years. Yesterday the American Petroleum Institute reported a 1.05 million barrel draw down in U.S. inventories. Today the...
Monday buy of SolarEdge Technologies in my Jubak Picks portfolio
I’ve been looking for a way out of this investing puzzle for a while and I think I’ve finally found one. SolarEdge Technologies (SEDG). I’m adding these shares to my Jubak Picks Portfolio on Monday. And I’ll be buying call options on these...
New calculation: Current cash position in Jubak Picks Portfolio
A couple of readers have asked me So what’s the cash position in Jubak Picks now? Very good question to ask at a time when we’re all trying to manage risk in a volatile market. So from here on out I’m going to calculate an approximate cash position...
Selling copper pick Freeport McMoran on fears of U.S./China tariff war
Freeport McMoRan Copper and Gold (FCX) was the third and last copper stock I added to my portfolios back in January 12, 2018–after Southern Copper (SCCO) and First Quantum Minerals (FQMLF). I added so much copper since copper prices were soaring in 2017–up...
Little spillover (yet) from Concho acquisition of Permian producer RSPP
Today Concho Resources (CXO) announced the acquisition of RSP Permian (RSPP) to create the biggest oil and natural gas producer from the shales of the Permian Basin. The $9.5 billion all stock deal represents a 29% premium to the Tuesday close for RSP Permian. That...Goldman Sachs turns bullish on gold
Goldman Sachs has turned positive on gold for the first time in five years. “Our commodities team believes that the dislocation between the gold prices and U.S. rates is here to say,” Goldman Sachs says. Drivers for higher gold prices include signs of an...
Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash
Turning around a portfolio can take a frustratingly long time. The Jubak’s Picks portfolio has had a performance problem since 2014. But I think I’ve finally put a recovery in place. The total return on the portfolio was 13.1% in 2017. That still badly...
How to manage risk in this market when the traditional risk safe havens aren’t working
If you spend a significant part of your day staring at your computer to watch the markets, you know that, perplexingly, the traditional safe havens for mitigating portfolio risk haven’t been working very well. For example, gold, which is supposed to go up when...
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely...
Holding Incyte in my Jubak Picks portfolio for mid-year catalysts
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out–results from critical drug trials weren’t likely to be reported for two years. The reason to...
Selling Acadia Pharmaceuticals out of my Jubak Picks portfolio
Today I’m selling Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio. I have a 13.52% loss on this position since I added the shares to the portfolio on November 15, 2016. There are short- and long-range reasons to sell. From a short-range perspective...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!